Healthy Women Clinical Trial
— FLAGOfficial title:
Vaginal Film Administration and Placement Study: FLAG
NCT number | NCT02908503 |
Other study ID # | PRO16010551 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2016 |
Est. completion date | February 14, 2017 |
Verified date | July 2018 |
Source | University of Pittsburgh |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate use of four different vaginal films - two sizes and two textures. The vaginal films have no active ingredients or medications. Information will be gathered about each film (i.e. ease of insertion, proper placement, opinions about each). The results of this study will help investigators determine which type of vaginal film to use (and how to write product instructions) for future studies.
Status | Completed |
Enrollment | 32 |
Est. completion date | February 14, 2017 |
Est. primary completion date | February 14, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: 1. Female, Age 18-40 2. Able and willing to provide written informed consent to be screened for and enrolled in the study. 3. Able and willing to provide adequate locator information at screening. 4. HIV-uninfected based on documented testing performed in the previous 6 months or by study staff at screening. 5. In general good health as determined by the site clinician 6. Agree to abstain from any intravaginal or rectal product or device or penetration (including vaginal, anal, or oral sex, masturbation, or sex toys) between each film insertion and the collection of the CVL approximately 24 hours later. Agree to be sexually abstinent for 48 hours prior to the study visits (from enrollment to visit 10). Sexual activity in the 48 hours prior to screening is acceptable. 7. Willingness to undergo all study-related assessments and procedures, including multiple speculum examinations, and follow all other study-related procedures 8. At screening and enrollment, agrees not to participate in other research studies involving drugs, medical devices, or vaginal products while enrolled in this trial and to abstain from vaginal product usage with the exception of tampons over the study period. Exclusion Criteria: Women who meet any of the following criteria by participant report will be excluded from the study. Of note, the study is limited to premenopausal women with an intact uterus because the mucosal immune environment differs substantially between pre- and post- menopausal women. Therefore, inclusion of post-menopausal women would introduce heterogeneity into the population. 1. Previous participation in a vaginal film study where participant was randomized to use film (i.e. FAME 02; FAME 04). Note: If participant was randomized to the gel arm, then she would be potentially eligible for participation in FLAG. 2. Menopausal at screening (as defined as amenorrhea for one year or more without an alternative etiology) 3. Hysterectomy 4. Participant report of any of the following at screening: 1. Known adverse reaction to any of the study products (ever) 2. Known adverse reaction to latex (ever) 3. Non- therapeutic injection drug use in the 12 months prior to screening 4. Surgical procedure involving the pelvis in the 90 days prior to screening (includes dilation and curettage or evacuation, and cryosurgery; does not include cervical biopsy for evaluation of an abnormal pap smear or IUD placement) 5. Participation in a drug, spermicide and/or microbicide study in the 30 days prior to screening or anticipated participation in an investigational drug study in the next 8 weeks 6. Currently pregnant or pregnancy within 90 days prior to screening 7. Lactating 8. Use of a diaphragm, NuvaRing®, or spermicide for contraception 5.) Urogenital infection or suspected infection within 14 days of enrollment including: symptomatic candidiasis, trichomonas vaginalis, and symptomatic bacterial vaginosis; or cervical infection, including Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), or mucopurulent cervicitis; syphilis; HSV lesions, or other sores (Note: participants seropositive for HSV without active lesions will not be excluded); acute pelvic inflammatory disease; urinary tract infection 6. Antibiotic or antifungal therapy (vaginal or systemic) within 7 days of enrollment 7. Menses or other vaginal bleeding at the time of enrollment* or expecting menses in the 5 days after enrollment. *Note, for women with monthly cycles, every attempt will be made to enroll these participants in the first half of their menstrual cycle. Women who have vaginal bleeding at the scheduled Enrollment Visit may return at a different date to be re-examined and possibly enrolled provided they are still within the screening window (maximum of 30 days between screening and enrollment) and meet all criteria. 8. Any condition that, in the opinion of the Investigator, would preclude provision of consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives |
Country | Name | City | State |
---|---|---|---|
United States | Magee-Womens Hospital of UPMC | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pittsburgh | Bill and Melinda Gates Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | correct insertion of vaginal films | assessed by examination | approximately 2 months | |
Primary | ease of insertion of vaginal film | assessed by questionnaire | approximately 2 months | |
Secondary | experience prior to film insertion | as assessed by participant interviews | approximately 2 months | |
Secondary | glycome/innate anti-HIV activity evaluation | laboratory testing including cervicovaginal lavage | approximately 2 months | |
Secondary | experience during film insertion | as assessed by participant interviews | approximately 2 months | |
Secondary | experience after film insertion | as assessed by participant interviews | approximately 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02575209 -
Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects
|
N/A | |
Active, not recruiting |
NCT03124160 -
Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard
|
Phase 3 | |
Completed |
NCT01879891 -
Exercise Intensity, Metabolic Rate and Insulin Sensitivity
|
N/A | |
Not yet recruiting |
NCT06395064 -
The Effect of Dimenhydrinate on Postoperative Nausea and Vomiting After Abdominal Hysterectomy: Randomized-controlled Trial
|
N/A | |
Completed |
NCT02720783 -
Tolerability and Pharmacokinetic Study of Econazole Nitrate Plus Benzydamine HCl Vaginal Pessary
|
Phase 1 | |
Recruiting |
NCT04143659 -
A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception
|
Phase 1 | |
Completed |
NCT01764412 -
Study of Serum Hepcidin Rate Variations During Menstrual Cycle
|
N/A | |
Completed |
NCT05777265 -
The Effects of 16-Week Circuit Training in Healthy Women
|
N/A | |
Completed |
NCT05777252 -
Effects of 16-Week Circuit Training in Healthy Women
|
N/A | |
Completed |
NCT03147703 -
Timing of Food Intake Impacts Daily Rhythms of Human Saliva Microbiota
|
N/A | |
Recruiting |
NCT05994599 -
Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring
|
Phase 1 | |
Not yet recruiting |
NCT03961412 -
A Family-based Intervention to Improve Pap Test Screening Among Under-screened Chinese American Immigrant Women
|
Early Phase 1 | |
Completed |
NCT01293591 -
Garlic Intake And Biomarkers Of Cancer Risk
|
N/A | |
Completed |
NCT02268032 -
Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve
|
Phase 1 | |
Completed |
NCT02994602 -
Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males
|
Phase 1 | |
Completed |
NCT04189796 -
Jarlsberg Cheese Compared to Camembert Cheese
|
N/A | |
Recruiting |
NCT03432416 -
Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring
|
Phase 2 | |
Unknown status |
NCT01809405 -
Validation of Sexual Function Scale in Female Cancer
|
N/A | |
Completed |
NCT03412617 -
Diets, Metabolic Profile and Gut Microbiota Among Indonesian Women in Minangkabau and Sundanese-ethnic Community
|
N/A | |
Completed |
NCT02112903 -
Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women
|
Phase 1 |